OSH101
A proteasome inhibitor - also known as PS1, originally researched and developed as a treatment for skeletal system disorders and hair loss, by OsteoScreen. The patent was sold to Neosil, and the name of the compound was changed to NEOSH101. It reached Phase 2 in the clinical trials, where it appeared to be a very potent growth stimulant. Neosil was then bought by Peplin Pharmaceuticals, which later was acquired by LEO Pharma. The research and development ended with Neosil...